SCYNEXIS Inc
SCYX0.627USD
-0.003-0.56%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
26.31MMarket Cap
LossP/E TTM
More Details of SCYNEXIS Inc Company
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.
SCYNEXIS Inc Info
Ticker SymbolSCYX
Company nameSCYNEXIS Inc
IPO dateMay 02, 2014
CEOAngulo (David)
Number of employees28
Security typeOrdinary Share
Fiscal year-endMay 02
Address1 Evertrust Plaza
CityJERSEY CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07302-6548
Phone12018845485
Websitehttps://www.scynexis.com/
Ticker SymbolSCYX
IPO dateMay 02, 2014
CEOAngulo (David)
Company Executives of SCYNEXIS Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Ivor Macleod, CPA
Mr. Ivor Macleod, CPA
Chief Financial Officer
Chief Financial Officer
71.40K
-30.69%
Mr. Guy Macdonald
Mr. Guy Macdonald
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
55.00K
+71.88%
Mr. Armando Anido
Mr. Armando Anido
Independent Director
Independent Director
48.00K
+92.00%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
47.00K
+95.83%
Dr. Ann F. Hanham, Ph.D.
Dr. Ann F. Hanham, Ph.D.
Independent Director
Independent Director
46.62K
+97.37%
Mr. David C. Hastings
Mr. David C. Hastings
Independent Director
Independent Director
46.18K
+99.21%
Mr. Scott A. Sukenick, J.D.
Mr. Scott A. Sukenick, J.D.
Chief Legal Officer, General Counsel
Chief Legal Officer, General Counsel
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. David Angulo, M.D.
Dr. David Angulo, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Philippe Tinmouth
Mr. Philippe Tinmouth
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ivor Macleod, CPA
Mr. Ivor Macleod, CPA
Chief Financial Officer
Chief Financial Officer
71.40K
-30.69%
Mr. Guy Macdonald
Mr. Guy Macdonald
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
55.00K
+71.88%
Mr. Armando Anido
Mr. Armando Anido
Independent Director
Independent Director
48.00K
+92.00%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
47.00K
+95.83%
Dr. Ann F. Hanham, Ph.D.
Dr. Ann F. Hanham, Ph.D.
Independent Director
Independent Director
46.62K
+97.37%
Mr. David C. Hastings
Mr. David C. Hastings
Independent Director
Independent Director
46.18K
+99.21%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Avidity Partners Management LP
7.98%
Kingdon Capital Management, L.L.C.
5.33%
The Vanguard Group, Inc.
4.20%
Federated Hermes Global Investment Management Corp.
3.77%
Geode Capital Management, L.L.C.
1.00%
Other
77.71%
Shareholders
Shareholders
Proportion
Avidity Partners Management LP
7.98%
Kingdon Capital Management, L.L.C.
5.33%
The Vanguard Group, Inc.
4.20%
Federated Hermes Global Investment Management Corp.
3.77%
Geode Capital Management, L.L.C.
1.00%
Other
77.71%
Shareholder Types
Shareholders
Proportion
Hedge Fund
14.57%
Investment Advisor
6.98%
Investment Advisor/Hedge Fund
6.44%
Individual Investor
2.16%
Research Firm
0.09%
Other
69.76%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
106
10.05M
23.95%
-3.55M
2025Q2
120
12.22M
31.31%
-3.15M
2025Q1
133
12.41M
31.82%
-4.90M
2024Q4
136
12.64M
33.32%
-10.36M
2024Q3
137
15.37M
41.19%
-4.80M
2024Q2
138
16.05M
43.14%
-5.28M
2024Q1
139
16.82M
45.23%
-5.52M
2023Q4
135
18.46M
50.25%
-3.63M
2023Q3
136
18.83M
51.36%
-3.62M
2023Q2
129
19.59M
54.27%
+67.28K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Avidity Partners Management LP
1.23M
2.93%
--
--
Jun 30, 2025
Kingdon Capital Management, L.L.C.
2.24M
5.34%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.66M
3.95%
--
--
Jun 30, 2025
Federated Hermes Global Investment Management Corp.
5.12M
12.2%
+2.22M
+76.74%
Sep 30, 2025
Geode Capital Management, L.L.C.
418.46K
1%
-1.02K
-0.24%
Jun 30, 2025
Acadian Asset Management LLC
424.50K
1.01%
-18.56K
-4.19%
Jun 30, 2025
Angulo (Gonzalez David)
323.28K
0.77%
+23.00K
+7.66%
Apr 09, 2025
BlackRock Institutional Trust Company, N.A.
334.65K
0.8%
-82.19K
-19.72%
Jun 30, 2025
AMH Equity, Ltd.
261.08K
0.62%
-365.96K
-58.36%
Jun 30, 2025
Yakira Capital Management, Inc.
189.80K
0.45%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 16, 2020
Merger
10→1
Jul 16, 2020
Merger
10→1
Jul 16, 2020
Merger
10→1
Jul 16, 2020
Merger
10→1
Date
Type
Ratio
Jul 16, 2020
Merger
10→1
Jul 16, 2020
Merger
10→1
Jul 16, 2020
Merger
10→1
Jul 16, 2020
Merger
10→1
FAQs
Who are the top five shareholders of SCYNEXIS Inc?
The top five shareholders of SCYNEXIS Inc are:
Avidity Partners Management LP holds 1.23M shares, accounting for 2.93% of the total shares.
Kingdon Capital Management, L.L.C. holds 2.24M shares, accounting for 5.34% of the total shares.
The Vanguard Group, Inc. holds 1.66M shares, accounting for 3.95% of the total shares.
Federated Hermes Global Investment Management Corp. holds 5.12M shares, accounting for 12.20% of the total shares.
Geode Capital Management, L.L.C. holds 418.46K shares, accounting for 1.00% of the total shares.
Avidity Partners Management LP holds 1.23M shares, accounting for 2.93% of the total shares.
Kingdon Capital Management, L.L.C. holds 2.24M shares, accounting for 5.34% of the total shares.
The Vanguard Group, Inc. holds 1.66M shares, accounting for 3.95% of the total shares.
Federated Hermes Global Investment Management Corp. holds 5.12M shares, accounting for 12.20% of the total shares.
Geode Capital Management, L.L.C. holds 418.46K shares, accounting for 1.00% of the total shares.
What are the top three shareholder types of SCYNEXIS Inc?
The top three shareholder types of SCYNEXIS Inc are:
Avidity Partners Management LP
Kingdon Capital Management, L.L.C.
The Vanguard Group, Inc.
Avidity Partners Management LP
Kingdon Capital Management, L.L.C.
The Vanguard Group, Inc.
How many institutions hold shares of SCYNEXIS Inc (SCYX)?
As of 2025Q3, 106 institutions hold shares of SCYNEXIS Inc, with a combined market value of approximately 10.05M, accounting for 23.95% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.35%.
What is the biggest source of revenue for SCYNEXIS Inc?
In --, the -- business generated the highest revenue for SCYNEXIS Inc, amounting to -- and accounting for --% of total revenue.
